Tacrolimus reduces peptidyl-prolyl isomerase activity by binding to the immunophilin FKBP12 (FK506 binding protein) creating a new complex. This FKBP12-FK506 complex interacts with and inhibits calcineurin thus inhibiting both T-lymphocyte signal transduction and IL-2 transcription.
Inhibition of T-Lymphocytes activation leads to no antibodies production and eventually no rejection of transplanted organs / no other immunological reactions.
- Cardiac transplant rejection
- Kidney transplant rejection
- Liver transplant rejection
- Small Bowel transplant rejection
- Pancreas transplant rejection
- Lung transplant rejection
- Trachea transplant rejection
- Skin transplant rejection
- Bone marrow transplant rejection
- Cornea transplant rejection
- Limb transplant rejection
- Ulcerative colitis, a form of inflammatory bowel disease
- Eczema, particularly atopic dermatitis
- Psoriasis
Of several minor side effects, the important side effect is Diabetes Mellitus.
Another considerable effect - increase in the severity of existing Viral, fungal and bacterial infections and increased vulnerability to opportunistic fungal and viral infections.
i-TACROL capsules are available in strengths of 0.5 mg, 1.0 mg, 2.0 mg & 5.0 mg.
Box containing 5 Strips of 10 capsules each